Home
Therapy Pipeline
- Immuno-Oncology
- Pain
Research
Team
News
About
- Contact Us
- About Us
More

Home
Therapy Pipeline
- Immuno-Oncology
- Pain
Research
Team
News
About
- Contact Us
- About Us
More

- Login
- Sign Up

Archive for 2020

Syntrix Pharmaceuticals > 2020

News
Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies
January 6, 2020 - by Syntrix
Researchers at the Fred Hutchinson Cancer Research Center and the National Institutes of Health (NIH) independently showed SX-682 eradicates pivotal…

0
Syntrix

Search for:

Recent Posts

New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer
Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies
Syntrix Pharmaceuticals to Present Positive Desmetramadol Trial Results at the 2019 Pain Management SUMMIT
Syntrix Announces Dosing of First Patient in Phase 1/2 Clinical Trial of SX-682 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Melanoma
Syntrix Reports Positive Clinical Trials Showing Desmetramadol Has the Analgesic and Side Effect Profile of Tramadol Without Its Metabolic Liabilities

Syntrix Pharmaceuticals
215 Clay Street NW
Suite B-5
Auburn, WA 98001

©2024 All Rights Reserved

NIH Required Policy for Managing Conflicts of Significant Financial Interest

Recent Articles

New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer
Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies

Home
Team
Research
Therapy Pipeline
- Pain
- Immuno-Oncology
Apply

Get in touch

TEL: 253-833-8009
FAX: 253-833-8127 email: info@syntrixbio.com